objective To study the effect and toxicity of S-1 combined with Oxaliplatin regimen and ECF regimen on advanced gastric cancer. Method 58 patients with advanced gastric cancer were divided into two groups randomly,30 patients in treatment group with S-1 combined with Oxaliplatin regimen;S-1 (80 mg/( m2 ·d)po bid d1-14 ),Oxaliplatin(130 mg/m2 ,ivgtt,2 h)were given,repeated every 21 days. 28 patients in control group with EPI regimen:EPI(epirubicin,50 mg/m2,ivgtt,d1),5-FU(fluorouracil,600 mg/m2,civ,120 h),DDP (cisplatin,60 mg/m2,iv,d1)were given,repeated every 21 days. The short term curative effect,TTP(Time To disease Progression),OS(O-verall Survival)and toxicity of the two regimens were analyzed. Results The response rate( RR)of treatment group and control group were 46. 7%(14/30)and 35. 7%(10/28),respectively. The disease controlling rate( DCR)of treatment group and control group were 83. 3%(25/30)and 78. 6%(22/28),respectively. The median TTP was 5. 7 months in treatment group and 5. 5 months in control group. The medi-an survival time was 8. 1 months in treatment group and 7. 8 months in control group. There was no significant deference( P>0. 05 ). Major side effect of the two groups had significant deference(P<0. 05). Conclusion S-1 combined with Oxaliplatin as a new neoadjuvant chemo-therapy,is an effective and safe therapy in advanced gastric cancer.%目的：观察替吉奥联合奥沙利铂方案与ECF方案治疗晚期胃癌疗效及不良反应。方法：将58例晚期胃癌患者随机分为两组，治疗组采用口服替吉奥胶囊80 mg/（ m2·d），分两次口服，第1天~第14天，停药7 d；奥沙利铂130 mg/m2，连续静脉滴注2 h，21 d为1个周期。对照组采用表柔比星50 mg/m2，静脉滴注，第1天；氟尿嘧啶600 mg/m2，持续输液泵滴入120 h，顺铂60 mg/m2，静脉注射，第1天；21 d为1个周期。比较两组间的近期疗效及不良反应。结果：治疗组和对照组的疾病缓解率（ RR）分别为46.7%（14/30）和35.7%（10/28）；疾病控制率（DCR）分别为83.3%（25/30）和78.6%（22/28）；疾病进展时间（TTP）分别为5.7个月和5.5个月，总生存期（OS）分别为8.1个月（5~16个月）和7.8个月（4.8~15个月），两组比较差异无统计学意义（P＞0.05）。两组不良反应主要为白细胞减少、中性粒细胞减少、血红蛋白减少、血小板减少、恶心呕吐、腹泻、色素沉着、黏膜炎、皮疹、脱发、心律失常、周围神经炎等，差异有统计学意义（ P＜0.05）。结论：替吉奥联合奥沙利铂方案治疗晚期胃癌有较好的疗效及安全性。
展开▼
